SCHEMBL30765762

SCHEMBL30765762

O=C(O)Cn1c(-c2ccccc2)ncc(-c2nc3c(s2)CCCC3)c1=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
LMNA P02545 3/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GLA P06280 2/20 0.42
KDM4E B2RXH2 2/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.40
F2RL3 Q96RI0 1/20 0.40
FFAR4 Q5NUL3 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SLC27A1 Q6PCB7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765674 0.89 ALDH1A1 (0.42) ALDH1A1LMNANPC1RAB9ASMN1; SMN2
SCHEMBL30765677 0.77 KDM4E (0.49) ALDH1A1GLAKDM4EHPGDALOX15
SCHEMBL31558529 0.71 F10 (0.34) ALDH1A1LMNANPC1RAB9ASMN1; SMN2
SCHEMBL17332419 0.69 NPC1 (0.51) ALDH1A1LMNANPC1RAB9ASMN1; SMN2
SCHEMBL6239360 0.69 CMA1 (0.53) KDM4EHSD17B10
Hydrochloric Acid SCHEMBL6805327 0.68 CMA1 (0.53) KDM4EHSD17B10
SCHEMBL6804111 0.68 CMA1 (0.53) KDM4EHSD17B10
SCHEMBL30765587 0.66 KDM4E (0.42) ALDH1A1KDM4EHPGDALOX15KMT2A
SCHEMBL7965688 0.65 KDM4E (0.45) ALDH1A1SMN1; SMN2KDM4EGAAHPGD
SCHEMBL6241617 0.65 KDM4E (0.44) ALDH1A1LMNARAB9AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed